Press releaseBusiness Wire
Emergent BioSolutions
EBS · NYSE
$6.29−$0.07 (−1.10%)TodayMarket closed ·
Prev close $6.36
Latest news
- Press releaseBusiness Wire
Emergent BioSolutions to Report Third Quarter 2026 Financial Results on November 2, 2026
- News
'Russia Denies Report of Second Case of Illness in Siberia' - Bloomberg
- NewsErica Kollmann
Novavax Shorts on Edge as Russia Plague Fears Spread
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
- Press releaseGlobe Newswire
Emergent BioSolutions Reinforces Commitment to Opioid Overdose Education and Preparedness on International Overdose Awareness Day
- News
World Health Organization Director General Determined That The Ebola Epidemic In DRC Still Meets Criteria Of Public Health Emergency Of International Concern, But Not Those Of A Pandemic Emergency
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
- Press releaseBusiness Wire
Emergent BioSolutions Inc. (EBS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
- Press releaseBusiness Wire
Securities Fraud Investigation Into Emergent BioSolutions Inc. (EBS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
- Press releaseBusiness Wire
EBS Investors Have Opportunity to Join Emergent BioSolutions Inc. Fraud Investigation with SBS Law
- Press releasePRNewswire
Emergent BioSolutions (EBS) Securities Investigation Notice - Levi & Korsinsky
- Press releaseGlobe Newswire
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Emergent BioSolutions (EBS)
- Press releaseBusiness Wire
EBS Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Emergent BioSolutions (EBS)
- Press releasePRNewswire
EBS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Emergent BioSolutions
- Press releasePRNewswire
Emergent BioSolutions Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Emergent BioSolutions (EBS)
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- Press releaseGlobe Newswire
Emergent BioSolutions Reports Second Quarter 2026 Financial Results
- News
'White House Adds Pandemic Response Staff as Ebola Cases Rise' - Bloomberg News
- News
FDA Broadens Access to Over-The-Counter Naloxone Nasal Spray for Opioid Overdose
- News
Emergent BioSolutions Q1 2026 Earnings Call: Complete Transcript
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- News
Emergent BioSolutions Q1 Adj. EPS $0.21 Beats $(0.25) Estimate, Sales $156.100M Beat $145.000M Estimate
- Press releaseGlobe Newswire
Emergent BioSolutions Reports First Quarter 2026 Financial Results
- News
Emergent BioSolutions Receives Singapore's Health Sciences Authority Approval For Expanded Indication For ACAM2000
- Press releaseGlobe Newswire
Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox
- News
Emergent BioSolutions Signs Multi-Year, ~$50M Agreement With SAB Biotherapeutics For Development And Manufacturing Of SAB-142, SAB's Lead Program In Clinical Development For Autoimmune Type 1 Diabetes
- Press releaseGlobe Newswire
Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142
- News
Emergent BioSolutions Signs ~$34.5M Agreement With Substipharm Biologics Over Drug Substance Production For Its Japanese Encephalitis Vaccine
- Press releaseGlobe Newswire
Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States
- NewsAvi Kapoor
Nasdaq Down Over 1%; Dell Shares Jump After Q4 Results
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- NewsAvi Kapoor
Dow Dips Over 600 Points; US Producer Prices Increase In January
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- Press releaseGlobe Newswire
Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results
- NewsVandana Singh
Emergent BioSolutions Wins FDA Approval For New Narcan Multipacks To Expand Overdose Access
- Press releaseGlobe Newswire
Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access
- NewsAvi Kapoor
How To Earn $500 A Month From American Express Stock Ahead Of Q2 Earnings
- NewsAvi Kapoor
How To Earn $500 A Month From Johnson & Johnson Stock Ahead Of Q2 Earnings
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.